BACKGROUND: Adrenaline-producing tumors are mostly characterized by a sudden release of catecholamines with episodic symptoms. Noradrenergic ones are usually less symptomatic and characterized by a continuous overproduction of catecholamines that are released into the bloodstream. Their effects on the cardiovascular system can thus be different. The aim of this study was to determine the prevalence of cardiovascular complications by catecholamine phenotype. METHODS: We retrospectively analyzed data on the prevalence of cardiovascular events in 341 consecutive patients with pheochromocytoma and paraganglioma treated from 1995 to 2023. Biochemical catecholamine phenotype was determined based on plasma or urinary catecholamines and metanephrines. RESULTS: According to the phenotype, 153 patients had noradrenergic pheochromocytoma and paraganglioma and 188 had adrenergic pheochromocytoma and paraganglioma. In the whole sample, the incidence of serious cardiovascular complications was 28% (95 patients), with no difference between the phenotypes or sexes. The noradrenergic phenotype had significantly more atherosclerotic complications (composite end point of type 1 myocardial infarction and symptomatic peripheral artery disease; odds ratio, 3.58 [95% CI, 1.59-8.83]; P=0.003), while the adrenergic phenotype more often had type 2 myocardial infarction and takotsubo-like cardiomyopathy (OR, 0.24 [95% CI, 0.09-0.57]; P=0.002). These changes remained even after adjustment for conventional risk factors of atherosclerosis. CONCLUSIONS: We found a 28% incidence of cardiovascular complications in a consecutive group of patients with pheochromocytoma and paraganglioma. Patients presenting with a noradrenergic phenotype have a higher incidence of atherosclerotic complications, while the adrenergic phenotype is associated with a higher incidence of acute myocardial damage due to takotsubo-like cardiomyopathy.

• MeSH
• adrenergní látky MeSH
• ateroskleróza * komplikace   MeSH
• fenotyp MeSH
• feochromocytom * diagnóza   MeSH
• infarkt myokardu * MeSH
• kardiomyopatie * MeSH
• katecholaminy MeSH
• lidé MeSH
• metanefrin MeSH
• nádory nadledvin * patologie   MeSH
• paragangliom * komplikace   MeSH
• retrospektivní studie MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH

• Klíčová slova
• NAFLD - (non - alcoholic fatty liver disease), MAFLD -metabolicky asociovaná tuková choroba jater, MASLD-metabolicky asociovaná steatotická choroba jater,
• MeSH
• lidé MeSH
• metabolický syndrom * diagnóza   klasifikace   komplikace   patofyziologie   MeSH
• nealkoholová steatóza jater * diagnóza   etiologie   patofyziologie   MeSH
• oxidační stres MeSH
• rizikové faktory MeSH
• zánět MeSH
• ztučnělá játra etiologie   patofyziologie   MeSH
• Check Tag
• lidé MeSH

INTRODUCTION: SARS-CoV-2 respiratory infection is associated with significant morbidity and mortality, especially in hospitalized high-risk patients. We aimed to evaluate the effects of treatment options (vitamin D, anticoagulation, isoprinosine, ivermectin) on hospital mortality in non-vaccinated patients during the 2021 spring wave in the Czech Republic. METHODS: Initially, 991 patients hospitalized in the period January 1, 2021, to March 31, 2021, with PCR-confirmed SARS-CoV-2 acute respiratory infection in two university and five rural hospitals were included in the study. After exclusion of patients with an unknown outcome, a total of 790 patients entered the final analysis. The effects of different treatments were assessed in this cohort by means of propensity score matching. RESULTS: Of the 790 patients, 282 patients died in the hospital; 37.7% were male and 33.3% were female. Age, sex, state of the disease, pneumonia, therapy, and several comorbidities were matched to simulate a case-control study. For anticoagulation treatment, 233 cases (full-dose) vs. 233 controls (prophylactic dose) were matched. The difference in mortality was significant in 16 of the 50 runs. For the treatment with isoprinosine, ivermectin, and vitamin D, none of the 50 runs led to a significant difference in hospital mortality. CONCLUSION: Prophylactic-dose anticoagulation treatment in our study was found to be beneficial in comparison with the full dose. Supplementation with vitamin D did not show any meaningful benefit in terms of lowering the hospital mortality. Neither ivermectin nor, isoprinosine was found to significantly decrease hospital mortality.

• MeSH
• antikoagulancia terapeutické užití   MeSH
• COVID-19 * MeSH
• inosin pranobex * MeSH
• ivermektin terapeutické užití   MeSH
• lidé MeSH
• retrospektivní studie MeSH
• SARS-CoV-2 MeSH
• studie případů a kontrol MeSH
• tendenční skóre MeSH
• vitamin D terapeutické užití   MeSH
• vitaminy MeSH
• Check Tag
• lidé MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH

• MeSH
• aortální aneurysma diagnóza   klasifikace   komplikace   MeSH
• chronická kritická ischemie končetin diagnóza   farmakoterapie   terapie   MeSH
• nemoci aorty * diagnóza   klasifikace   komplikace   MeSH
• onemocnění periferních arterií * diagnóza   etiologie   farmakoterapie   klasifikace   terapie   MeSH
• plicní embolie diagnóza   farmakoterapie   MeSH
• plicní hypertenze diagnóza   farmakoterapie   MeSH
• žilní insuficience diagnóza   farmakoterapie   klasifikace   MeSH
• žilní tromboembolie diagnóza   farmakoterapie   klasifikace   prevence a kontrola   MeSH
• Publikační typ
• přehledy MeSH

• MeSH
• index tělesné hmotnosti MeSH
• metabolický syndrom * diagnóza   epidemiologie   metabolismus   MeSH
• metabolismus MeSH
• obezita * diagnóza   dietoterapie   etiologie   farmakoterapie   terapie   MeSH
• Publikační typ
• přehledy MeSH

• MeSH
• ateroskleróza prevence a kontrola   MeSH
• dietoterapie klasifikace   MeSH
• dyslipidemie * diagnóza   etiologie   farmakoterapie   krev   MeSH
• farmakoterapie klasifikace   MeSH
• lipidy krev   MeSH
• poruchy metabolismu lipidů diagnóza   farmakoterapie   klasifikace   MeSH
• Publikační typ
• přehledy MeSH

Výbor České společnosti pro aterosklerózu (ČSAT) přináší ve výběru nejdůležitější informace z článku F. Kronenberga et al (Atherosclerosis 2023; 374), kterým autoři reagovali na otázky kladené odbornou veřejností ke Konsenzu EAS o lipoproteinu(a) vydaného roku 2022 (Eur Heart J 2022; 43). Autoři zformulovali 30 nejčastěji kladených otázek, na něž stručně odpověděli a připojili k odpovědím vysvětlující komentář. Výbor ČSAT z těchto komentářů vybral nejdůležitější informace relevantní pro české prostředí.

The Committee of the Czech Society for Atherosclerosis (CSAT) has selected the most important information from the article by F. Kronenberg et al (Atherosclerosis 2023; 374), by which the authors responded to questions posed by the professional community on the EAS Consensus on lipoprotein(a) published in 2022 (Eur Heart J 2022; 43). The authors formulated the 30 most frequently asked questions, answered them briefly, and added explanatory commentary to the answers. From these comments, the CSAT Committee selected the most relevant information for the Czech environment.

• MeSH
• ateroskleróza * patologie   prevence a kontrola   MeSH
• kardiovaskulární nemoci patologie   prevence a kontrola   MeSH
• lidé MeSH
• lipoprotein (a) * analýza   genetika   účinky léků   MeSH
• rizikové faktory kardiovaskulárních chorob MeSH
• směrnice pro lékařskou praxi jako téma MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• práce podpořená grantem MeSH

• Klíčová slova
• EMPAGLIFLOZIN,
• MeSH
• adherence k farmakoterapii MeSH
• benzhydrylové sloučeniny MeSH
• diabetes mellitus 2. typu * diagnóza   dietoterapie   farmakoterapie   MeSH
• fixní kombinace léků * MeSH
• glifloziny terapeutické užití   MeSH
• glukosidy MeSH
• inzulin glargin terapeutické užití   MeSH
• komplikace diabetu farmakoterapie   MeSH
• lidé středního věku MeSH
• lidé MeSH
• metformin terapeutické užití   MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• Publikační typ
• kazuistiky MeSH

Vysokoškolská učebnice, která se zaměřuje na vnitřní lékařství.

• MeSH
• vnitřní lékařství MeSH

• Konspekt
• Patologie. Klinická medicína
• Učební osnovy. Vyučovací předměty. Učebnice
• NLK Obory
• vnitřní lékařství
• NLK Publikační typ
• učebnice vysokých škol
• kolektivní monografie

SARS-CoV-2 respiratory infection is associated with significant morbidity and mortality in hospitalized patients. We aimed to assess the risk factors for hospital mortality in non-vaccinated patients during the 2021 spring wave in the Czech Republic. A total of 991 patients hospitalized between January 2021 and March 2021 with a PCR-confirmed SARS-CoV-2 acute respiratory infection in two university hospitals and five rural hospitals were included in this analysis. After excluding patients with unknown outcomes, 790 patients entered the final analyses. Out of 790 patients included in the analysis, 282/790 (35.7%) patients died in the hospital; 162/790 (20.5) were male and 120/790 (15.2%) were female. There were 141/790 (18%) patients with mild, 461/790 (58.3%) with moderate, and 187/790 (23.7%) with severe courses of the disease based mainly on the oxygenation status. The best-performing multivariate regression model contains only two predictors-age and the patient's state; both predictors were rendered significant (p < 0.0001). Both age and disease state are very significant predictors of hospital mortality. An increase in age by 10 years raises the risk of hospital mortality by a factor of 2.5, and a unit increase in the oxygenation status raises the risk of hospital mortality by a factor of 20.

• Publikační typ
• časopisecké články MeSH